Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy.


Department of Medicine, Columbia University Irving Medical Center, 650 West 168th Street, Black Building 8-816, New York, NY 10032, USA. Electronic address: [Email]


Immunotherapy has drastically improved the prognosis of many patients with cancer, but it can also lead to severe immune-related adverse events. Biomarkers, which are molecular markers that indicate a patient's disease outcome or a patient's response to treatment, are therefore crucial to helping clinicians weigh the potential benefits of immunotherapy against its potential toxicities. Immunohistochemistry (IHC) has thus far been a powerful technique for discovery and use of biomarkers such as CD8+ tumor-infiltrating lymphocytes. However, IHC has limited reproducibility. Thus, if more IHC-based biomarkers are to reach the clinic, refinement of the technique using multiplexing or automation is key.


Checkpoint inhibition,Immunohistochemistry,Immunotherapy,Predictive and prognostic biomarkers,